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The capsid (CA) sequence of human immunodeficiency virus type 1 (HIV-1) Gag protein consists of two independently folded domains named
the N-terminal domain (NTD) and C-terminal domain (CTD) that are connected by a flexible linker. Most of the CTD sequence adopts rigid
structure except for the last 11 amino acids (positions 354 to 364) that are disordered even in the context of the downstream SP1 and nucleocapsid
(NC) sequence. Although disordered, this short peptide region plays a crucial role in HIV-1 replication. In this study, we identified three second-
site mutations within Gag named A238T, G358S, and N373K that rescued a deleterious mutation R362A located at the C-terminus of CA. A238T
is located within the NTD of CA, G358S and N373K are positioned proximal to R362A. One of the mechanisms underlying this compensation
event is correction of reduced packaging of viral RNA into the R362A mutated viruses, as shown by the results of RNase protection assays, native
Northern blots experiments as well as filter-binding assays. These data suggest that one potential function for the C-terminal disordered sequence
of CA in HIV-1 replication is to regulate HIV-1 RNA packaging.
D 2005 Elsevier Inc. All rights reserved.Keywords: HIV-1; Gag; RNA packagingIntroduction
Human immunodeficiency virus type 1 (HIV-1) encodes the
Gag protein that is capable of forming virus-like particles in the
absence of other viral proteins (Gheysen et al., 1989). During or
shortly after virus budding from cells, Gag is cleaved by viral
protease to generate mature and infectious viruses. Proteolysis
of Gag leads to the production of matrix (MA), capsid (CA),
nucleocapsid (NC), p6, as well as two short spacer peptides
termed SP1 and SP2. MA forms a thin layer underneath virus
envelope, while CA constructs the shell of the conical core in
which NC associates with viral genomic RNA (Freed, 1998).
An important role of MA is to target Gag to cellular
membranes where Gag assembles. This activity is attributed to
the N-terminal sequence of MA that consists of two structural0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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the second glycine as well as the multiple basic residues of the
first 31-amino-acid region. These two motifs are defined as the
membrane-binding domain (Gottlinger et al., 1989; Mervis et
al., 1988; Spearman et al., 1994; Zhou et al., 1994). The
myristyl group anchors Gag into the lipid bilayer, whereas the
downstream basic residues further stabilize Gag-membrane
association via electrostatic interaction with the negatively
charged phosphor groups of the membrane lipids.
CA is capable of self-association and generates regular geo-
metric structures exhibiting a hexagonal lattice pattern (Ganser
et al., 1999; Li et al., 2000). Of the two independently folded CA
domains, the N-terminal domain forms the hexameric rings, and
the C-terminal domain links one ring to its six neighbors. This
property of CA not only underlies the generation of the mature
core but may also guide the Gag precursor to produce the
immature capsid structure (Mayo et al., 2002, 2003). In this
sense, CA regulates spatial arrangement of Gag within virion.
NC is a highly basic protein featured by two CCHC zinc
finger motifs. In the context of the Gag precursor, NC recruits5) 190 – 200
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X. Guo et al. / Virology 343 (2005) 190–200 191two copies of viral genomic RNA into each virus particle
(Berkowitz et al., 1996). These two RNA molecules, non-
covalently linked at their 5V ends as a dimer, in turn serve as a
scaffold for Gag aggregation (Burniston et al., 1999; Campbell
and Rein, 1999; Campbell and Vogt, 1995; Cimarelli et al.,
2000; Khorchid et al., 2002; Sandefur et al., 2000; Zhang et al.,
1998). This scaffold activity of viral genomic RNA can be
executed by non-viral RNA species (Muriaux et al., 2001).
P6 is located at the C-terminus of Gag and plays vital roles in
virus budding (Gottlinger et al., 1991; Huang et al., 1995). This
region harbors two short motifs, i.e., P(T/S)AP and LXXLF,
that bind to cellular proteins TSG101 (tumor susceptibility gene
101) and AIP1, respectively (Garrus et al., 2001; Martin-
Serrano et al., 2001; Strack et al., 2003; VerPlank et al., 2001;
von Schwedler et al., 2003). These two cellular proteins recruit
factors that are involved in vacuolar protein sorting to the sites
of virus assembly and together catalyze budding and release of
virus particles from cellular membranes. The relevant motifs of
p6 are named late budding domain (Freed, 2002).
Importance of the aforementioned Gag domains in virus
production is further manifested by successive construction of
a Gag derivative containing minimal Gag sequences that
suffice to produce virus-like particles (Accola et al., 2000).
This minimal Gag construct comprises the first seven amino
acids of MA and the C-terminal domain of CA, SP1, NC, and
p6, of which NC and p6 can be changed to heterogeneous
sequences without impeding virus production. For example,
NC can be replaced either by the leucine zipper sequence from
the yeast transcription factor GCN4 or by the Bacillus subtilis
MtrB protein domain (Accola et al., 2000; Zhang and Barklis,
1997). Similarly, p6 can be changed to different types of late
domain such as PPPY from Rous sarcoma virus (Accola et al.,
2000). These results together implicate the indispensable role
for the C-terminal domain of CA and SP1 in generation of
virus-like particles.
The C-terminal domain of CA contains four helices that fold
into a globular structure appended by a disordered fragment
consisting of the last 11 amino acids (positions 354 to 364)
(Gamble et al., 1997; Newman et al., 2004; Worthylake et al.,
1999). Regardless of its disordered structure, 8 out of these 11
amino acids have been shown to be vital for virus particle
production (Liang et al., 2002, 2003; Melamed et al., 2004). To
gain insight into the underlying mechanisms, we have studied
the R362A mutation located within this disordered region, and
we successfully identified three second-site mutations within
Gag named A238T, G358S, and N373K that rescued R362A.
Results of further studies revealed that one major mechanism
underlying this compensation event involved restoration of
wild-type RNA packaging to the R362A mutated virus.
Results
The R362A mutation is rescued by the A238T, G358S, and
N373K second-site mutations
The R362A mutation is located at the C-terminus of CA and
has been shown to inhibit virus replication (Liang et al., 2002).In the present study, we have cultured the R362A mutant in
MT-2 cells until the virus regained wild-type infectivity.
Sequencing analysis of proviral DNA from the reverted
virus indicated retention of the R362A mutation as well as
emergence of three second-site mutations within Gag, i.e.,
A238T, G358S, and N373K (Fig. 1A). The A238T mutation is
located within the NTD of CA and participates in formation of
helix 5. G358S belongs to the 355-GGPG-358 motif and is four
amino acids upstream of R362A. N373K resides within SP1
and is eleven residues downstream of R362A (Fig. 1A).
To test whether these three second-site mutations can rescue
R362A, they were inserted into the R362A HIV-1 cDNA clone
to generate a series of recombinant DNA constructs (Fig. 1B).
Both wild-type and mutated HIV-1 cDNAwere transfected into
COS-7 cells, and virus particles thus generated were used to
infect MT-2 cells. The results in Fig. 1B show that levels of RT
activity in culture fluids peaked at day 6 for wild-type BH10. In
contrast, the R362A mutant generated detectable levels of RT
activity only by day 16 post-infection. Each of the A238T,
G358S, and N373K mutations markedly stimulated growth of
virus R362A, although A238T enhanced viral replication to a
lesser extent than either G358S or N373K (Fig. 1B). The three
second-site mutations together restored wild-type replication
capacity to R362A (Fig. 1B). We further measured infectivity
of the aforementioned viruses in single-round infection through
performing MAGI assays (Kimpton and Emerman, 1992). The
R362A mutation decreased virus infectivity by approximately
threefold; this defect was corrected to wild-type levels in the
presence of the second-site mutations A238T, G358S, and
N373K (Fig. 1C). It is noticed that the extent of reduction in
virus infectivity measured for the R362A mutant in the MAGI
assays is less pronounced than the replication defect observed
in infected MT-2 cells. This is likely because the results of
MAGI assays reflect the level of Tat protein produced by
infected virus, whereas replication curves are a measurement of
virus yield following infection. Overall, these results show that
A238T, G358S, and N373K suffice to restore wild-type
infectivity to the R362A mutant.
The A238T, G358S, and N373K second-site mutations enhance
particle production of the R362A virus
Results of our previous studies showed that the R362A
mutation caused three to fourfold decrease in virus particle
production upon transfection of viral cDNA into COS-7 cells
(Liang et al., 2002). These data were reproduced in transfection
experiments by measuring levels of either viral p24 (CA) or
reverse transcriptase (RT) that was associated with extracellular
virus particles (Fig. 2A). This defect partially accounts for
diminished infectivity of the R362Avirus. Consistent with their
rescuing activity, the A238T, G358S, and N373K second-site
mutations together increased yield of the R362A mutated virus
particles to wild-type levels, as shown by the results of Western
blots and ELISA (Fig. 2A). When virus particles were
examined with electron microscopy, lower numbers of virus
particles were seen for the R362A mutant as compared with the
wild-type and the A238T/G358S/N373K/R362A recombinant
Fig. 1. Rescue of the R362A mutation by the A238T, G358S, and N373K second-site mutations. (A) Illustration of the R362A, A238T, G358S, and N373K
mutations within Gag. A domain structure of Gag is presented to show the MA, CA, SP1, NC, SP2, and p6 regions. Number of the amino acids refers to the first
methionine of MA. (B) Replication kinetics of the mutated and wild-type viruses within MT-2 cells. Viruses equivalent to 5 ng of p24(CA) were used to infect 5 
105 MT-2 cells. Viral growth was monitored through measuring RT (reverse transcriptase) activity in culture supernatants at various times. Growth curves shown
represent one of the two infection experiments that were performed with virus stocks collected from different transfection experiments. (C) Virus infectivity as
determined in MAGI assays. A number of 2  104 HeLa-CD4-LTR-h-gal cells were exposed to the mutated or wild-type viruses equivalent to 10 ng of p24(CA) for
48 h before the numbers of blue cells were scored. The results shown are from one infection experiment. The relative infectivity between viruses is consistent in three
infection studies that were performed with virus stocks obtained from different transfection experiments.
X. Guo et al. / Virology 343 (2005) 190–200192virus. In addition, the R362A mutated virus particles contained
electron-dense cores that frequently assumed acentric position
and barely exhibited conical shape (Fig. 2B). Thus, the R362A
mutation not just diminishes the yield of virus particles but also
moderately affects the core structure.The R362A virus packages lower levels of viral genomic RNA
It is noted that the N373K suppressor mutation, located 11
amino acids downstream of R362A, introduces a basic residue
into the SP1 region. This observation suggests importance of
Fig. 2. Particle production by the mutated and wild-type viruses. COS-7 cells were transfected with the mutated or wild-type HIV-1 DNA clones. Levels of Gag proteins associated with cells (A) and virus particles (B)
were measured with Western blots or ELISA using anti-HIV-1 p24 (CA) antibody. Levels of virion-associated reverse transcriptase (RT) were either determined in Western blots using anti-HIV-1 RT antibody or by
measuring RT activity. Relative levels of virus particles generated by each DNA construct were calculated on the basis of ELISA data and levels of RT activity with those of the wild-type BH10 set as 100. (C)
Observation of virus particles with transmission electron microscopy. Transfected COS-7 cells were processed following the procedure for electron microscopy. Particles with electron-dense cores are shown for the
wild-type BH10 as well as the A238T/G358S/N373K/R362A and R362A mutated viruses. The bar represents a scale of 200 nm. More than 60 particles from each type of viruses were examined to determine core
position as well as core shape.
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X. Guo et al. / Virology 343 (2005) 190–200194basic charge for the function of the R362 residue, and that this
function may relate to Gag–RNA interaction and viral RNA
packaging considering the close proximity of R362 and N373
to the downstream NC region. To test this hypothesis, viral
RNA was extracted from either the mutated or wild-type virus
particles followed by analysis in an RNase protection assay
(Fig. 3A). The results of Fig. 3B show that levels of viral
genomic RNA incorporated into the R362A mutated virus
particles were three to fourfold less than those for the wild-type
BH10. This viral RNA packaging defect is not attributed to
altered viral RNA expression within cells, since comparable
levels of full length and spliced viral RNAwere detected within
either R362A- or BH10-transfected cells (Fig. 3B). When
A238T, G358S, and N373K were combined with R362A, viral
RNA packaging was corrected to wild-type levels (Fig. 3B). It
is noted that combinations A238T/N373K and G358S/N373KFig. 3. Effect of the R362A mutation on HIV-1 RNA packaging. (A) Illustration of
Sizes of RNA fragments protected for viral genomic RNA and spliced RNA are sho
with virus particles or with transfected cells. Results from cell-associated viral RNA
corresponding to the genomic, spliced, and total viral RNA are indicated on the left s
used in the experiments. Levels of virion-associated genomic RNA were determine
using the AlphaImager v5.5 program. Results shown are the average from three inexerted a more potent effect in this regard than A238T/G358S.
Therefore, N373K contributes to the largest extent among these
three suppressor mutations in fixing defective viral RNA
packaging; nonetheless, the optimal compensation effect can
only be achieved when all three mutations are present.
To validate the aforementioned observation, we measured
levels of viral RNAwithin the R362A mutated viruses through
performing native Northern blots experiment. Viral RNA was
prepared from mutated or wild-type virus particles equivalent
to 150 ng HIV-1 p24 (CA) and separated on native agarose
gels. Results of Northern blots using labeled HIV-1 DNA
probes revealed markedly diminished levels of viral RNA
associated with the R362A mutated viruses as compared with
wild-type BH10. An approximately fourfold reduction in
packaging of the R362A viral RNA was calculated on the
basis of RNA band intensity from the results of threethe HIV-1 RNA probes used in RNase protection assay (Russell et al., 2003).
wn. (B) RNase protection assays to measure viral RNA levels either associated
are shown for R362A, BH10, and A238T/G358S/N373K/R362A. RNA bands
ide of the gels. The band of the probe is shown to indicate its excessive amount
d on the basis of relative band intensity as quantified by digital image analysis
dependent experiments.
X. Guo et al. / Virology 343 (2005) 190–200 195independent native Northern blots (data not shown), which is
consistent with the data obtained in RNase protection assays,
and is also reflected by the three to fourfold decrease of virus
infectivity shown by the results of MAGI assays (Fig. 1C).
Again, the three second-site mutations together corrected this
RNA packaging defect (Fig. 4A).
Interestingly, the R362A mutated viruses contained only
dimeric RNA. When viral RNA was treated at different
temperatures prior to separation on native agarose gels, the
results showed that the R362A viral RNA dimer displayed the
same stability as the wild-type RNA dimer (Fig. 4B).
Therefore, the R362A mutation restricts viral RNA packaging
but does not disrupt viral RNA dimerization. This observation
implicates that each R362A virus particle always incorporates
two copies of viral RNA albeit with low efficiency compared to
wild-type virus, and these two viral RNA molecules can be
converted to stable RNA dimer when NC is released duringFig. 4. The R362A mutation does not affect dimerization of HIV-1 RNA. (A)
Native Northern blots to assess levels of viral RNA dimerization. RNA samples
from purified virus particles equivalent to 150 ng p24(CA) were separated on
0.9% agarose gels followed by hybridization with HIV-1 DNA probes.
Positions of RNA dimer and monomer are indicated on the left side of the
gel. Sizes of RNA markers are also shown. (B) Measuring stability of viral
RNA dimers. Viral RNA was first treated at various temperatures (40-, 45-,
50-, and 55 -C) for 10 min in the presence of 100 mM NaCl before being
separated on agarose gels.virus maturation. It is noted that viral RNA prepared from virus
particles dissociated into small RNA fragments following heat
treatment at 50 -C or 55 -C. This might be due to the presence
of nicks in viral RNA. It remains to be tested whether the
R362A mutation has any effect on this RNA fragmentation
event.
The R362A attenuates Gag-viral RNA binding
We next studied whether the RNA packaging defect seen for
the R362A mutant is a result of decreased Gag–RNA binding.
Toward this end, we exploited a Gag derivative termed
(mini)Gag to measure the affinity of Gag for viral RNA in
filter-binding assays. The (mini)Gag contains the first 2–7
amino acids of MA, the C-terminal domain of CA (amino acids
278 to 364), SP1 (amino acids 365 to 378), and the NC
sequence (amino acids 379 to 433) (Roldan et al., 2004). This
Gag version has previously been shown to display high affinity
for HIV-1 RNA packaging sequences (Roldan et al., 2004). We
inserted the R362A mutation alone or together with G358S and
N373K into (mini)Gag such as to generate (mini)Gag-R362A,
(mini)Gag-G358S/R362A, (mini)Gag-N373K/R362A, and
(mini)Gag-G358S/N373K/R362A, respectively (Fig. 5A).
The affinity of the wild-type or the mutated (mini)Gag proteins
for HIV-1 RNA sequence (nt 223 to 506, containing viral RNA
packaging elements SL1 to SL4) was measured in filter-
binding assays with PolyI/PolyC as non-specific competitors.
On the basis of their Kd values (Fig. 5B), the wild-type (WT)
and mutated (mini)Gag proteins are ranked as WT  G358S/
N373K/R362A < N373K/R362A < G358S/R362A  R362A.
This result demonstrates that the R362A mutation diminishes
the binding of Gag with HIV-1 RNA packaging signals. The
compensatory mutation N373K fixes this defect to approxi-
mately wild-type levels, whereas the G358S mutation exerts
minor effect in this regard.
Discussion
In this study, we made two major findings. First, attenuated
replication of the R362A mutated virus is rescued by the
A238T, G358S, and N373K second-site mutations within Gag.
Second, the R362A mutation suppresses HIV-1 RNA packag-
ing, and this defect is fixed by the aforementioned compen-
satory mutations.
R362 is the third amino acid to the C-terminus of CA and
represents one of the last 11 amino acids that are disordered in
the structures calculated for CA146–231, CA146–231-SP1 and
CA(CTD)-SP1-NC (Gag residues 276 to 431) molecules
(Momany et al., 1996; Newman et al., 2004; Worthylake et
al., 1999). Interestingly, NMR analysis of a synthetic peptide
bearing Gag sequence at amino acid positions 345 to 392
revealed a 23-amino acid a-helix that encompasses the last
seven residues of CA, the entire 14 amino acids of SP1, and the
first two residues of NC (Morellet et al., 2005). This latter
observation is consistent with the results of computer modeling
and genetic analysis (Accola et al., 1998). It is likely that the
CA-SP1-NC junction sequence can either exist in a structurally
Fig. 5. Effects of the R362A mutation on Gag–RNA binding as measured in filter-binding assays. (A) Illustration of the recombinant (mini)Gag protein. A 6xHis-
Tag is attached to the N-terminus of Gag sequence. The purified Gag derivatives were separated on SDS-PAGE followed by staining with Coomassie Brilliant Blue.
Sizes of protein ladders are shown on the left side of the gels. (B) Binding of (mini)Gag to HIV-1 RNA probes. Either the mutated or wild-type (WT) (mini)Gag
proteins were incubated with 1 nM HIV-1 RNA probes internally labeled with [32P]UTP. An amount of 20 ng/Al of PolyI/PolyC was added as non-specific
competitors. HIV-1 probes associated with (mini)Gag were captured in filter-binding assay, and their relative levels are plotted against Gag concentration (nM).
Alternatively, the inverse of protein concentration was plotted against the inverse of saturation factor (SF) as described (Bailey, 1979). The Kd values were calculated
for each type of Gag tested and were used to determine the relative RNA binding affinity. Results shown are for experiments performed at 25 -C. Kd value of AM
range was calculated when the binding reactions were performed on ice (data not shown). Under both conditions, the wild-type (WT) (mini)Gag displayed a Kd value
of three to fourfold lower than the (mini)Gag-R362A.
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such as Gag binding to RNA. Both features may be required
for this region to exert distinct functions at different stages of
Gag assembly.
We noted that the G358S and N373K suppressor mutations
reside, together with R362A, within the putative a-helix
spanning the CA-SP1-NC junctions (Fig. 1A). More precisely,
since G358S is 4 amino acids upstream of R362A and N373K is
11 amino acids downstream of R362A, these three mutated
residues are actually positioned on the same side of the helix
(Fig. 6). According to NMR structures (Morellet et al., 2005),
residues H359, R362, E366, Q370, and N373 together
constitute a hydrophilic surface, opposite to a hydrophobic
surface involving residues L364, M368, V371, T372, A375,
and M378 (Fig. 6). Predictably, the R362A mutation diminishes
the hydrophilic extent of the related surface. By virtue of their
sitting on the same helical surface with R362A, the G358S and
N373K second-site mutations must have increased the hydro-
philic levels to the hydrophilic interface and thus help to re-
establish relevant Gag–Gag interactions (Fig. 6).
HIV-1 RNA packaging involves specific recruitment of viral
genomic RNA from the abundant cellular RNA pool into virusparticles. This selection process depends on high affinity of NC
for viral RNA packaging signals that are located within the 5V
untranslated region such as SL2 and SL3, a concept that is well
illustrated by the NMR structures calculated for the NC/SL2
and NC/SL3 complexes (Amarasinghe et al., 2000; De Guz-
man et al., 1998). Since generation of immature virus particles
precedes virus maturation, NC must have acted in the context
of the Gag precursor to recognize viral RNA. On the basis of
this concept, NC can be assisted by other sequences of Gag
when exercising its viral RNA packaging activity. One
evidence in support of this view is that the SP1 region has
been shown to regulate HIV-1 RNA packaging. For example, a
chimeric HIV-1/HIV-2 Gag with HIV-2 MA-CA and HIV-1
SP1-NC-p6 showed higher preference for packaging HIV-1
RNA than Gag chimera containing HIV-2 MA-CA-SP1 and
HIV-1 NC-p6 (Kaye and Lever, 1998). Moreover, the T12I
amino acid substitution at the C-terminus of SP1 enabled the
SL1-deleted viruses to exclude spliced viral RNA from
encapsidation (Russell et al., 2003). We now show that HIV-
1 RNA packaging is restricted by an R362A mutation located
at the C-terminus of CA. This latter result does not come as a
surprise but rather presents further support for involvement of
Fig. 6. Computer modeling to show restoration of the hydrophilic surface where both the R362A mutation as well as the compensatory mutations G358S and N373K
are located. Residues comprising the hydrophilic and hydrophobic surfaces are highlighted in blue and red, respectively. Structure of wild-type Gag sequence
(positions 345–392) (Morellet et al., 2005) is used to calculate structures for the R362A and G358S/N373K/R362A mutated sequences using ESyPred3D web server
(Lambert et al., 2002).
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RNA considering that R362 and the SP1 sequence are both
located within the same helical structure.
In contrast to its adverse effect on HIV-1 RNA packaging,
the R362A mutation does not disrupt dimerization of HIV-1
RNA (Fig. 4). The observation that retroviral RNA dimeriza-
tion can occur in the face of diminished RNA packaging has
also been made in other retroviruses such as murine leukemia
virus (MLV) (Hibbert et al., 2004; Levin and Rosenak, 1976).
For instance, cellular mRNA molecules containing packaging
signals from MLV were incorporated as dimers into virus
particles irrespective of the severely diminished packaging
efficiency of these chimeric mRNAs compared with MLV
genomic RNA (Hibbert et al., 2004). In addition, treatment of
cells with actinomycin D resulted in diminished viral RNA
packaging; yet, virion-associated viral genomic RNA was
almost entirely dimeric (Levin and Rosenak, 1976). These
results suggest that retroviruses have evolved stringent
mechanisms to maintain diploid even when RNA packaging
efficiency is compromised.
Conceivably, at least two mechanisms are involved in
reinforcing retrovirus diploid: not just that dimerization has to
take place prior to packaging, but also that viral RNA dimer
must be preferable for packaging than monomer. The first
hypothesis is supported by the result of a recent study showing
that the palindrome within the dimerization initiation signal
was protected from Me2SO4 modification in the context of
HIV-1 RNA derived from infected cells (Paillart et al., 2004),
which suggests that this palindrome has paired with its
counterpart of a second HIV-1 RNA molecule within cells
before viral RNA packaging occurs. The second mechanism is
manifested by NMR structures solved for the MLV NCcomplex with the ‘‘core encapsidation’’ RNA fragment
(D’Souza and Summers, 2004). In particular, a short nucleotide
stretch ‘‘306-UCUG-309’’ was identified to exhibit high
affinity for NC (Kd = 75 T 12 nM), but was exposed only
when two viral RNA molecules formed a dimer, which
implicates higher packaging efficiency for dimeric viral RNA
than for monomeric ones.
In summary, results of this study demonstrate that the
R362A mutation leads to reduction in viral RNA packaging as
well as in viral replication. This finding suggests an important
hitherto unappreciated role for the CA-SP1 boundary sequence
in Gag–RNA interaction. Our data also support the notion that
HIV-1 RNA forms premature dimers prior to packaging into
virus particles.
Materials and methods
Plasmid DNA construction
The BH10 infectious HIV-1 cDNA clone was employed as
starting material to generate the following mutations. The
A238T, G358S, and N373K second-site mutations were
combined with R362A by PCR through use of the primer
pairs A238T-A/Sph-S (5V-GGTACTAGTAGT TCC TGT TAT
GTC ACT TCC-3V/5V-AGT GCA TCC AGT GAT GCA GGG
CC-3V), G358S-S/NC-A (5V-GGA GTA GGA GGA CCC AGC
CAT AAG GCA GC-3V/5V-TTA GCC TGT CTC TCA GTA
CAATC-3V) and N373K-S (5V-GC CAA GTA ACA AAG TCA
GCT ACC ATA ATG-3V)/NC-A, respectively. The mutated
nucleotides are underlined in relevant primers. The PCR
products resulting from use of A238T/Sph-S were employed
as mega primers in a second round of PCR together with the
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template. Similarly, the G358S/NC-A and N373K/NC-A PCR
products were used as primers in a second-round PCR together
with the Sph-S sense primer. The final PCR products were
digested with restriction enzymes SphI and ApaI and inserted
into the BH10 DNA construct that had been digested with
the same two enzymes. The same strategy was used to geneQ
rate DNA constructs such as A238T/G358S/R362A, A238T/
N373K/R362A, G358S/N373K/R362A, and A238T/G358S/
N373K/R362A.
DNA clones (mini)Gag, (mini)Gag-R362A, (mini)Gag-
G358S/R362A, (mini)Gag-N373K/R362A, and (mini)Gag-
G358S/N373K/R362A were created by PCR through use of
primer pair (mini)Gag-F/NC-R (5V-CAC CGG TGC GAG
AGC GTC AGT AAG CCC TAC CAG CAT TCT GGA
C-3V/5V-TTA ATT AGC CTG TCT CTC AGT ACA ATC-3V).
The BH10 DNA clones containing the relevant mutations
were employed as DNA templates in PCR. Amplified DNA
fragments were then inserted into the expression vector Topo
100-D (Invitrogen, Burlington, ON, Canada).
Cell culture, transfection, and infection
COS-7 and HeLa cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) and MT-2 cells in RPMI 1640,
supplemented with 10% fetal calf serum. COS-7 cells were
transfected using Lipofectamine (Invitrogen) in accordance
with the manufacturer’s instructions. Virus infection assay was
performed through infecting 5  105 MT-2 cells in a 2-ml
volume using an amount of virus equivalent to 5 ng of p24
(CA). Cells were washed twice 2 h after infection and cultured
in 10 ml of complete RPMI 1640 medium. Culture fluids were
collected at various times, and reverse transcriptase (RT)
activity was measured to monitor virus replication.
Virus infectivity was also measured in multinuclear activa-
tion of a galactosidase indicator (MAGI) assay (Kimpton and
Emerman, 1992). HeLa-CD4-LTR-h-gal cells were plated in
24-well plates (2  104 cells/well) and infected with an amount
of virus equivalent to 10 ng of p24 (CA) per well. Each
infection was performed in triplicate. Three independent
infections were conducted using virus stocks obtained from
independent transfection experiments. Forty-eight hours post-
infection, cells were fixed with 1% formaldehyde 0.2%
glutaraldehyde in phosphate-buffered saline and stained with 5-
bromo-4-chloro-3-indolyl-h-d-galactoside (X-Gal) for 45 min.
Infectivity was calculated as the number of blue cells counted
per well.
RNase protection assay
The experiments were performed as described previously
(Russell et al., 2003). In brief, HIV-1 RNA probes were
internally labeled with [a-32P]UTP (ICN) through in vitro
transcription of BspE1-linearized RPA1 plasmid DNA using
T7-MEGAshortscript kit (Ambion Inc., Austin, Texas, USA).
Viral RNA samples that were prepared from purified virus
particles equivalent to 25 ng of p24 (CA) incubated at 42 -Covernight with labeled riboprobes (105 cpm) followed by
digestion with single-strand-specific RNases (RPA II kit,
Ambion Inc.). An amount of 250 ng RNA samples from cells
transfected with either wild-type BH10, or the mutated R362A
and A238T/G358S/N373K/R362A DNA was also assessed.
Protected RNA fragments were fractionated on 5% polyacryl-
amide-8 M urea gels and further visualized by autoradiography.
Relative intensity of each band was quantified by digital image
analysis using the AlphaImager v5.5 program.
Native Northern blots
The experiments were performed as previously described
(Russell et al., 2002). In brief, virus particles collected from
transfected COS-7 cells were clarified by centrifugation in a
Beckman GR-6S centrifuge at 3000 rpm for 30 min at 4 -C,
followed by ultracentrifugation through a 20% sucrose cushion
in a Beckman XL-80 ultracentrifuge with an SW41 rotor at
40,000 rpm for 1 h at 4 -C. Virus pellets were suspended in 300
Al of Tris (50 mM, pH 7.8)–NaCl (100 mM) buffer and then
treated in lysis buffer (50 mM Tris–HCl (pH 7.4), 10 mM
EDTA, 1% sodium dodecyl sulfate (SDS), 100 mM NaCl, 50
Ag of yeast tRNA/ml, 100 Ag of proteinase K/ml) for 30 min at
37 -C. Samples were extracted twice with phenol–chloro-
form–isoamylalcohol (25:24:1) and once with chloroform.
Viral RNA was precipitated in 2.5 volumes of 95% ethanol
with 0.3 M sodium acetate (pH 5.2). RNA pellets were washed
with 70% ethanol and dissolved in Tris (50 mM)–EDTA (10
mM) (pH 7.5) (TE) buffer. An amount of viral RNA equivalent
to 150 ng of HIV-1 p24 was fractionated on 0.9% native
agarose gels in 1 Tris–borate–EDTA (TBE) buffer at 100 V
for 4 h at 4 -C. Viral RNA was transferred onto nylon
membranes and detected through use of HIV-1 DNA probes
(nucleotide positions 1 to 2000) internally labeled with
[a-32P]dCTP (ICN, Irvine, CA, USA). To measure the stability
of RNA dimers, viral RNA samples were first incubated at
various temperatures such as 40 -C, 45 -C, 50 -C, and 55 -C in
a buffer containing 100 mM NaCl prior to electrophoresis on
native agarose gels.
Gag purification and filter-binding assays
The His-(mini)Gag contains a 6xHis tag at the N-terminus
followed by the first 2–7 amino acids of MA, the CTD of CA
(278–364), SP1 (365–378), and NC (379–433) (Fig. 5A).
This Gag derivative was purified as we described previously
(Roldan et al., 2004). In brief, after transforming E. coli BL21
(DE3), expression of His-(mini)Gag was induced with adding
IPTG. Three hours post-induction, the His-(mini)Gag proteins
were purified using nickel–nitrilotriacetic acid resin (Qiagen,
Mississauga, ON, Canada) in accordance with the manufac-
turer’s instructions. Purified His-(mini)Gag proteins were
refolded through dialysis in a buffer containing 0.5 M Tris–
HCl (pH8.0), 50 mM NaCl, 10 AM ZnCl2, 5 mM/0.5 mM
reduced/oxidized glutathione, 0.01% CHAPS at 4 -C for 3 h,
followed by centrifugation at 57,000  g to remove any
misfolded or aggregated Gag proteins (Roldan et al., 2004).
X. Guo et al. / Virology 343 (2005) 190–200 199Filter-binding experiments were performed as previously
described (Roldan et al., 2004). HIV-1 RNA sequence
(nucleotide positions 223 to 506) was generated through in
vitro transcription in the presence of [a-32P]UTP (ICN) using
the Megashortscript kit (Ambion). Various amounts of purified
His-(mini)Gag proteins were incubated with 1 nM radiolabeled
probes in a buffer containing10 mM HEPES (pH 7.5), 100 mM
KCl, 1 mM MgCl2, 0.5 mM EDTA, 10 AM ZnCl2, 1 mM
dithiothreitol, 20 ng/Al Poly I/Poly C as non-specific compe-
titors, and 7.5% Ficoll. After incubation for 15 min at 25 -C,
the samples were filtered through 0.45 AM nitrocellulose disks
(Millipore, Nepean, ON, Canada). The filters were washed
twice with storage buffer (50 mM Tris (pH 8.0), 50 mM NaCl,
20% glycerol), levels of radioactivity that were retained on the
filters were quantified by liquid scintillation counting (Roldan
et al., 2004). The Kd values were calculated as described
(Bailey, 1979).
Electron microscopy
Transfected COS-7 cells were fixed with 2.5% glutaralde-
hyde and further treated with 4% osmium tetroxide. Thin
sections of the embedded samples were stained with lead
citrate and uranyl acetate and visualized using a JEOL JEM-
2000 FX transmission electron microscope equipped with a
Gatan 792 Bioscan 1024- by 1024-byte wide-angle multiscan
charge-coupled device camera.
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